From tumour heterogeneity to advances in precision treatment of colorectal cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 14, Issue 4, Pages 235-246
Publisher
Springer Nature
Online
2016-12-06
DOI
10.1038/nrclinonc.2016.171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
- (2017) Alan P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
- (2016) Loredana Vecchione et al. CELL
- Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
- (2016) Boyang Zhao et al. CELL
- Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database
- (2016) Lindsay A. Renfro et al. JOURNAL OF CLINICAL ONCOLOGY
- MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
- (2016) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?
- (2016) Lars A. Påhlman et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
- (2016) Piero Dalerba et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
- (2016) Pedro M. Enriquez-Navas et al. Science Translational Medicine
- The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial
- (2016) Chang Woo Kim et al. Trials
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- (2016) Marios Giannakis et al. Cell Reports
- LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer
- (2015) E. Elez et al. ANNALS OF ONCOLOGY
- LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
- (2015) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
- (2015) N. Normanno et al. ANNALS OF ONCOLOGY
- Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)
- (2015) Joost Huiskens et al. BMC CANCER
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Application of Evolutionary Principles to Cancer Therapy
- (2015) P. M. Enriquez-Navas et al. CANCER RESEARCH
- Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
- (2015) J. F. Linnekamp et al. CANCER RESEARCH
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
- (2015) Marc van de Wetering et al. CELL
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
- (2015) R. Yaeger et al. CLINICAL CANCER RESEARCH
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
- (2015) M. Peeters et al. CLINICAL CANCER RESEARCH
- Tankyrase Inhibition Blocks Wnt/ -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
- (2015) O. Arques et al. CLINICAL CANCER RESEARCH
- Role of First-Line Anti–Epidermal Growth Factor Receptor Therapy Compared With Anti–Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials
- (2015) Muhammad A. Khattak et al. Clinical Colorectal Cancer
- Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic review
- (2015) G.H. Lee et al. EJSO
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
- (2015) Lieke H J Simkens et al. LANCET
- Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
- (2015) Anne J Breugom et al. LANCET ONCOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
- (2015) Susanna Hegewisch-Becker et al. LANCET ONCOLOGY
- Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
- (2015) Elaine E. Storm et al. NATURE
- A Big Bang model of human colorectal tumor growth
- (2015) Andrea Sottoriva et al. NATURE GENETICS
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Serrated neoplasia—role in colorectal carcinogenesis and clinical implications
- (2015) Joep E. G. IJspeert et al. Nature Reviews Gastroenterology & Hepatology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wnt addiction of genetically defined cancers reversed by PORCN inhibition
- (2015) B Madan et al. ONCOGENE
- Porcupine inhibitor suppresses paracrine Wnt-driven growth ofRnf43;Znrf3-mutant neoplasia
- (2015) Bon-Kyoung Koo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases
- (2015) Fleur Weeber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial
- (2015) JP Maarten Burbach et al. Trials
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
- (2015) Karen Lise Garm Spindler et al. PLoS One
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
- (2014) H. Blons et al. ANNALS OF ONCOLOGY
- Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
- (2014) F. Ciardiello et al. ANNALS OF ONCOLOGY
- The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
- (2014) Jorine ’t Lam - Boer et al. BMC CANCER
- Association between KRAS mutation and lung metastasis in advanced colorectal cancer
- (2014) A A L Pereira et al. BRITISH JOURNAL OF CANCER
- MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors
- (2014) Paolo Luraghi et al. CANCER RESEARCH
- Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells
- (2014) S. Colak et al. CELL CYCLE
- Reconciliation of classification systems defining molecular subtypes of colorectal cancer
- (2014) Anguraj Sadanandam et al. CELL CYCLE
- Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells
- (2014) S Colak et al. CELL DEATH AND DIFFERENTIATION
- CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis
- (2014) Matilde Todaro et al. Cell Stem Cell
- Colorectal Cancer Stem Cells: From the Crypt to the Clinic
- (2014) Ann Zeuner et al. Cell Stem Cell
- Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS-RAF Mutations
- (2014) L. Zimmer et al. CLINICAL CANCER RESEARCH
- Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
- (2014) P. Laurent-Puig et al. CLINICAL CANCER RESEARCH
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- RSPO fusion transcripts in colorectal cancer in Japanese population
- (2014) Kazuya Shinmura et al. MOLECULAR BIOLOGY REPORTS
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer
- (2013) Matthias Maak et al. ANNALS OF SURGERY
- ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
- (2013) P Li et al. BRITISH JOURNAL OF CANCER
- A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation-Driven Colorectal Tumor Growth
- (2013) T. Lau et al. CANCER RESEARCH
- Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives
- (2013) Ana Custodio et al. CANCER TREATMENT REVIEWS
- Cancer heterogeneity—a multifaceted view
- (2013) Felipe De Sousa E Melo et al. EMBO REPORTS
- Dissecting cancer heterogeneity – An unsupervised classification approach
- (2013) Xin Wang et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
- (2013) Paul Roepman et al. INTERNATIONAL JOURNAL OF CANCER
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
- (2013) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A
- (2013) Fiorenza Lotti et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
- (2013) Eva Budinska et al. JOURNAL OF PATHOLOGY
- Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08
- (2013) Kay Pogue-Geile et al. JNCI-Journal of the National Cancer Institute
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
- (2013) Felipe De Sousa E Melo et al. NATURE MEDICINE
- A colorectal cancer classification system that associates cellular phenotype and responses to therapy
- (2013) Anguraj Sadanandam et al. NATURE MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
- (2013) J. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Defining Stem Cell Dynamics in Models of Intestinal Tumor Initiation
- (2013) L. Vermeulen et al. SCIENCE
- Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies
- (2013) C-W Fan et al. Cell Death & Disease
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555)
- (2012) Nuh N Rahbari et al. BMC CANCER
- Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
- (2012) Andreas Schlicker et al. BMC Medical Genomics
- A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice
- (2012) J. Waaler et al. CANCER RESEARCH
- Pharmacological Inhibition of the Wnt Acyltransferase PORCN Prevents Growth of WNT-Driven Mammary Cancer
- (2012) K. D. Proffitt et al. CANCER RESEARCH
- Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
- (2012) S. Julien et al. CLINICAL CANCER RESEARCH
- Cerebral Hemorrhage, Warfarin, and Intravenous tPA
- (2012) Mark J. Alberts JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency
- (2012) Sun Tian et al. JOURNAL OF PATHOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- The developing cancer stem-cell model: clinical challenges and opportunities
- (2012) Louis Vermeulen et al. LANCET ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Recurrent R-spondin fusions in colon cancer
- (2012) Somasekar Seshagiri et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Histological and Molecular Evaluation of Patient-Derived Colorectal Cancer Explants
- (2012) Joshua M. Uronis et al. PLoS One
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature
- (2011) Sabine Venderbosch et al. ANNALS OF SURGICAL ONCOLOGY
- Molecular Genetics of Colorectal Cancer
- (2011) Eric R. Fearon Annual Review of Pathology-Mechanisms of Disease
- Cancer Stem Cell Niche: The Place to Be
- (2011) T. Borovski et al. CANCER RESEARCH
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- A Review of Excision Repair Cross-complementation Group 1 in Colorectal Cancer
- (2011) Pierre Bohanes et al. Clinical Colorectal Cancer
- Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival
- (2011) Frank Benedix et al. DISEASES OF THE COLON & RECTUM
- Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer
- (2011) Sang Cheul Oh et al. GUT
- Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare Data
- (2011) Jennifer M. Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial
- (2011) Willem van Gijn et al. LANCET ONCOLOGY
- Microenvironmental regulation of stem cells in intestinal homeostasis and cancer
- (2011) Jan Paul Medema et al. NATURE
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
- Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
- (2010) Michael J. O'Connell et al. JOURNAL OF CLINICAL ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
- (2010) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
- (2010) Louis Vermeulen et al. NATURE CELL BIOLOGY
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- (2009) M Koopman et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis
- (2009) E. H. Huang et al. CANCER RESEARCH
- Adaptive Therapy
- (2009) R. A. Gatenby et al. CANCER RESEARCH
- A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
- (2009) Miriam Koopman et al. EUROPEAN JOURNAL OF CANCER
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Basis of Colorectal Cancer
- (2009) Sanford D. Markowitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?
- (2008) Robert A. Meguid et al. ANNALS OF SURGICAL ONCOLOGY
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
- (2008) L. Barault et al. CANCER RESEARCH
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers
- (2008) R. N. Jorissen et al. CLINICAL CANCER RESEARCH
- Clonality, Founder Mutations, and Field Cancerization in Human Ulcerative Colitis–Associated Neoplasia
- (2008) Simon J. Leedham et al. GASTROENTEROLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
- (2008) Scott J. Dylla et al. PLoS One
- Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity
- (2008) L. Vermeulen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now